For a Chinese plasma product, import into the Philippines is two questions. First, whether China will export it — covered in the export regulations and market-entry guide. Second, whether the Philippines will register and admit it. This page is about the second question.
The regulator and the law
The Food and Drug Administration (FDA) of the Philippines regulates medicines, vaccines and biologicals under Republic Act No. 3720 (as amended) and Republic Act No. 9711. Biological products — including vaccines, blood products and plasma-derived medicinal products — are handled through the FDA's Center for Drug Regulation and Research (CDRR) and require additional quality and comparability data over and above a standard chemical drug.
The authorisations you need
Three documents sit at the centre of a Philippine import, and they are often confused. They are separate, and all three matter:
| Authorisation | What it is | Who holds it |
|---|---|---|
| Certificate of Product Registration (CPR) | The FDA's authorisation for a specific product to be marketed and imported | The Philippine Marketing Authorisation Holder |
| License to Operate (LTO) | Licence to operate an establishment (importer/distributor) | The Philippine-registered entity |
| FDA Import Permit | Permit for each shipment of an overseas-manufactured product | The licensed importer |
The key constraint: the Marketing Authorisation Holder must be a Philippine-registered entity. A Chinese exporter cannot hold the Philippine registration. What the exporter contributes is the product file, and what the local holder contributes is the licence and the filing.
The dossier format
The Philippine FDA requires the ASEAN Common Technical Document (ACTD) format — the standard for the ASEAN region. The core file a Chinese exporter must supply is the same one described in the general market-entry guide:
- Certificate of Pharmaceutical Product — the WHO-format status evidence.
- The drug approval number, verifiable on the NMPA database.
- The batch release certificate — that the specific lot was state-released.
- GMP evidence for the manufacturing site.
- A certificate of analysis for the specific batch.
- The export mandate or authorisation naming the exporter.
For biologicals, the FDA also requires quality and comparability data beyond a conventional drug — a point to plan for before the dossier is assembled, not discovered at screening.
The sequence, end to end
| Step | What happens | Who does it |
|---|---|---|
| 1. Confirm exportability | Product is finished, registered, batch-released — not source plasma | Exporter + manufacturer |
| 2. Confirm importability | The Philippines admits this product class and there is a viable CPR path | Local holder + FDA |
| 3. Assemble the ACTD dossier | CPP, approval number, batch release, GMP, CoA, export mandate | Exporter provides; local holder adapts |
| 4. File for the CPR | Submit through the FDA, through the Philippine MAH | Local MAH |
| 5. Import & release | Ship with an FDA import permit, then release the batch for use | Licensed importer + FDA |
The Certificate of Product Registration is valid for five years and must be renewed at least 90 days before expiry. Post-approval changes — formulation, packaging or site — go through a variation application.
How a Chinese export agent fits in
Wanyoda's role is the export side of this sequence. We hold the written export mandates from NMPA-licensed manufacturers and coordinate the product file — approval number verification, CPP, batch release and GMP evidence — so the Philippine holder receives a complete, filing-ready dossier. We do not hold the Philippine registration, because by law it cannot be held by a foreign company; the appointed distributor is the licence holder.
What this means in practice: the fastest Philippine entry is one where the export-side product file is already complete and the local holder already has its LTO. Registration then becomes adaptation and filing rather than a long evidence-gathering exercise.
The Philippine constraint that matters most: the CPR is held locally. Choose an export partner whose product file is complete on day one, and the local filing is the only remaining variable.
Where Wanyoda already has Philippine records
Two products carry Philippine regulatory records that shorten this path. Rabies immunoglobulin holds Philippine GMP certification (2026), and Boya IVIG holds a Philippine GMP waiver. Human albumin and rabies vaccines are open territories where registration is initiated jointly with the appointed distributor. See the full picture on the Philippines market page.
Frequently asked questions
What authorisation is required to import a blood product into the Philippines?
The product must hold a Certificate of Product Registration (CPR) from the FDA of the Philippines, held by a Philippine-registered Marketing Authorisation Holder. The importing establishment also needs a License to Operate (LTO) and, for overseas-manufactured products, an FDA import permit.
What dossier format does the Philippine FDA require?
The Philippine FDA requires the ASEAN Common Technical Document (ACTD) format, supported by GMP evidence, a Certificate of Pharmaceutical Product, and compliant labelling. Biological products need additional quality and comparability data.
Can a foreign company hold the Philippine registration?
No. The Marketing Authorisation Holder must be a Philippine-registered entity with a valid License to Operate. The Chinese exporter supplies the product file, and the local holder adapts and files the dossier.
How long is a Certificate of Product Registration valid?
A Certificate of Product Registration in the Philippines is valid for five years and must be renewed at least 90 days before expiry.
Where to go next
- Philippines market page — the products with Philippine records and open territories.
- Certificate of Pharmaceutical Product — the document every dossier turns on.
- The destination-by-destination guide — how the Philippines compares to other markets.
- Open territories — where we are actively appointing Philippine partners.